Cargando…
Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
Federal regulatory agencies such as the United States Food and Drug Administration review pharmacological evidence to ensure the safety and efficacy of new and repurposed pharmaceuticals prior to market approval. The discussions, disagreements and procedural decisions contained within such reviews o...
Autores principales: | Eadie, Ashley L., Brunt, Keith R., Herder, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177063/ https://www.ncbi.nlm.nih.gov/pubmed/34087050 http://dx.doi.org/10.1002/prp2.794 |
Ejemplares similares
-
Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman
por: Faber, Eve S., et al.
Publicado: (2016) -
Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
por: Nikolic, Marina, et al.
Publicado: (2022) -
Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study
por: Jaffuel, Dany, et al.
Publicado: (2021) -
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
por: Jaffuel, Dany, et al.
Publicado: (2018) -
A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
por: Newhard, Daniel K., et al.
Publicado: (2018)